The identification of TNFRSF1A mutations as the genetic cause of TRAPS raised the possibility that blocking TNF—even though elevated TNF is not observed in most TRAPS patients [74]—could potentially represent the primary therapeutic strategy in TRAPS. The gene discussed is TNFRSF1A; the disease is TNF receptor 1-associated periodic fever syndrome.